Zacks Research Cuts Earnings Estimates for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Analysts at Zacks Research decreased their Q1 2025 earnings per share estimates for Zimmer Biomet in a research report issued on Monday, January 20th. Zacks Research analyst R. Department now expects that the medical equipment provider will earn $2.01 per share for the quarter, down from their prior forecast of $2.02. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2025 earnings at $8.46 EPS, Q1 2026 earnings at $2.25 EPS, Q2 2026 earnings at $2.33 EPS, Q4 2026 earnings at $2.32 EPS and FY2026 earnings at $9.10 EPS.

Other equities research analysts also recently issued research reports about the company. BTIG Research cut their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Barclays cut their target price on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Finally, Oppenheimer decreased their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $123.33.

Zimmer Biomet Stock Down 0.7 %

Shares of NYSE ZBH opened at $109.77 on Wednesday. The stock has a market cap of $21.85 billion, a P/E ratio of 20.87, a PEG ratio of 1.88 and a beta of 1.02. The business’s fifty day simple moving average is $107.85 and its 200-day simple moving average is $108.06. Zimmer Biomet has a 12-month low of $100.67 and a 12-month high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the prior year, the company earned $1.65 EPS. Zimmer Biomet’s revenue was up 4.1% on a year-over-year basis.

Institutional Trading of Zimmer Biomet

A number of institutional investors have recently added to or reduced their stakes in the stock. Dunhill Financial LLC lifted its position in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new position in Zimmer Biomet in the 3rd quarter valued at approximately $28,000. Bangor Savings Bank acquired a new position in Zimmer Biomet during the third quarter worth $31,000. Brooklyn Investment Group purchased a new stake in Zimmer Biomet during the third quarter worth $35,000. Finally, Quarry LP acquired a new stake in Zimmer Biomet in the second quarter valued at $53,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be issued a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.